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February 2016 Abstracts S23non-malignant cells. Analysis of PCNA structure revealed
that the L126-Y133 region forms part of a pocket suit-
able for binding by a small molecule. We designed and
tested a series of small molecules that target this binding
pocket and identiﬁed AOH1160, a potent PCNA inhibitor,
which kills small cell lung cancer (SCLC) cells at high
nanomolar concentrations, but causes no signiﬁcant
toxicity to a broad range of non-malignant cells up to a
concentration of 10 mM. AOH1160 is orally available to
animals and inhibits tumor growth without causing any
observable side-effects, including weight loss, in mice.
These studies demonstrated the feasibility of inhibiting
the growth of SCLC cells by targeting a speciﬁc region of
PCNA without causing unacceptable toxicity to normal
tissues. Further development of AOH1160 may lead to a
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Background: Lung cancer has the highest mortality
rates of all the cancers in Canada with a 5 year survival
rate of less than 15%. Asymptomatic in its early stages,
methods to screen high risk individuals are in dire need
to allow earlier diagnosis and curative intent treatment.
MicroRNAs (miRNAs) are small, non-coding strands of
RNA that are shown to lead to carcinogenesis when
dysregulated. They are promising candidates for bio-
markers as they are stable, detectable in small quantities
and are expressed in a tissue speciﬁc manner. Through
the use of a miRNA panel developed by our group that
demonstrated good sensitivity and speciﬁcity using
sputum as a medium to measure miRNA., we aimed to
compare the efﬁcacy of measuring miRNA in sputum and
blood to develop a miRNA proﬁle for non-small cell lung
cancer (NSCLC).
Objective: To examine miRNA proﬁles of NSCLC cases
versus healthy controls to compare the efﬁcacy of
sputum and blood for potential screening purposes us-
ing microarray analysis.
Methods: A case control study of stage I/II cancers,
matched with controls having similar smoking history,
age, and gender, was performed. Participants were
recruited at the Royal Alexandra Hospital in Edmon-
ton, Alberta, Canada. Both sputum and blood arecollected and analyzed via Qiagen miRNA kits. 10
cases and 10 controls miRNA samples were submitted
for microarray analysis. miRNAs were labelled, hy-
bridized, and quantiﬁed using single-color experi-
mental design. Speciﬁc miRNAs from past literature
were then compared in cases and controls using Mann
Whitney U test.
Results: Sputum does not have consistent levels of
miRNA present when compared to blood, and principle
component analysis (PCA) plots show more random
patterns in sputum when compared to blood. By using
heat maps and hierarchical clustering, no apparent
clusters are seen when compared cases and controls in
both sputum and blood. A type II error could be
responsible for this ﬁnding due to the small sample size.
In an independent analysis looking at speciﬁc miRNAs
seen to be dysregulated in past literature, miR-147a is
signiﬁcantly different in sputum, and miR-126-5p is
signiﬁcantly different in blood.
Conclusions: Microarray analysis shows that sputum
is less consistent when measuring miRNAs compared
to blood overall. These ﬁndings have already been
applied to the next phase of our research which will
examine miRNA levels in high risk individuals as a
means of establishing it as a robust screening test for
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Clinical trials with single agent immune checkpoint in-
hibitors, mainly the anti-PD-1 antibody, have achieved
noteworthy beneﬁt with an objective response rate in
17% of non-small cell lung cancer (NSCLC) patients.
However, minimal or no response in a large proportion
of patients suggest that additional immune suppression
pathways need to be identiﬁed in the tumor microenvi-
ronment to deﬁne combination immune therapies for
future therapeutic intervention. We have focused our
studies on the KRAS mutant subset, as it accounts for
>30% of NSCLC patients with high mortality rates due
to a conspicuous lack of effective FDA approved targeted
therapies.
To enable selection of appropriate immunother-
apies, we have performed comprehensive analysis of
immune microenvironments in a mouse model of
S24 Journal of Thoracic Oncology Vol. 11 No. 2SKRAS driven NSCLC, to identify various potential
mechanisms that may lead to effector T cell suppres-
sion. Validation of key ﬁndings in human KRAS ade-
nocarcinomas identiﬁed several dominant
immunosuppressive mechanisms employed by KRAS
tumors. These mechanisms include spatiotemporal
organization of immune cells (T cell exclusion/inclu-
sion, MDSCs, Macrophages), expression of speciﬁc co-
inhibitory checkpoints (PD1-PD-L1, LAG-3, TIM-3,
TIGIT), and additional components of T cell suppres-
sion (IDO, Arginase, Tregs). Identiﬁcation of concur-
rent dominant immune suppressive mechanisms
employed by KRAS tumors has allowed us to employ
rationally guided effective combination therapeutics,
which are being tested in exploratory trials in pre-
clinical models, together with immunomodulatory ac-
tion of conventional standard of care chemotherapy
and radiation therapy. Our approach is in line with
recent success of combination immunotherapies in
melanoma and colon cancer, and could impact the
selection of immunotherapies for treating mutant
KRAS NSCLC patients in the clinic.
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Background: The mutation proﬁle of many cancer-
related genes in the Mexican population of patients with
non-small cell lung cancer (NSCLC) remains largely un-
explored and also their relationship to many clinical
features of the patients. Next Generation Sequencing
(NGS) allows multiplexing for sequencing several genes
with higher sensitivity than other techniques and it is
increasingly applied in clinical research. Hypothesis: The
population of Mexican NSCLC patients presents a speciﬁc
mutation proﬁle in cancer-related genes that can be
better characterized by targeted NGS than by PCR and
may be related to clinical characteristics.
Objectives: To detect the presence of somatic mutations
by targeted NGS and PCR in Mexican patients with
NSCLC and ﬁnd its association with clinicopathological
features.Methods: Overall 31 tumor biopsies of Mexican patients
with NSCLC were analyzed. DNA was extracted from
biopsies using the Wizard Genomic DNA kit. DNA con-
centration was determined by Qubit. Quality control was
performed with the FFPE QC kit for formalin-ﬁxed,
parafﬁn-embedded samples. Genomic libraries were
constructed using the TruSeq Cancer Panel comprising
212 amplicons of 48 genes. Sequences were obtained in
a MiSeq sequencer. EFGR mutations were analyzed
alternatively by using real time PCR using the Rotor-
Gene Q and the Scorpions and ARMS technologies.
Results: We found mutations in 19 cancer-related
genes speciﬁc for the Mexican population. In 37% of
cases we found mutations in the EGFR gene, in exon 19
(17%), exon 21 (13%) and two rare mutations in exons
2 and 3. We found a correlation for the diagnosis of
mutations in the EGFR gene by PCR and NGS in seven
patients. EGFR mutations were detected in four patients
by NGS that were not detected by PCR. Additional
mutations were found mainly in TP53 in 12 patients
(40%), followed by mutations in the genes GNAQ
(33%), HNF1A (16%), VHL (13%) and KRAS (10%).
Several other mutations were detected in minor fre-
quencies i.e. 6% for CTNNB1, FGFR2, MET and
SMARCB1 and 3% of the cases for APC, BRAF, CDH1,
ERBB2, FGFR3, GNAS, PTEN and RB1. The clinicopath-
ological characteristics of the patients were a median
age of 65 years in a range of 37-82 years, 93% of
patients had adenocarcinoma with 34% of mixed sub-
type, 23% acinar, 17% poorly differentiated, 13% solid,
10% lepidic and 3% papilar. Metastatic NSCLC was
detected in 53% of the patients, mainly in bones and
brain (33%). Overall 70% were female, 55% were
exposed to wood-smoke and 41% were smokers.
The performance status of the patients was predomi-
nantly ECOG1 with 78%. Most patients (76%) were
diagnosed at a disease stage IV while 24% presented
stage IIIB. Treatment was established according the
mutational status of the patients, 60% was treated with
chemotherapy: Cisplatin-Paclitaxel (30%), Pemetrexed-
Carboplatin (17%), Gemcitabine-Carboplatin (9%) and
Vinorelbine-Cisplatin (4%). Tyrosine kinase inhibitor
(TKI) treatment consisted of Erlotinib (17%), Geﬁtinib
(13%) and Afatinib (10%). Concerning the relationship
with clinical characteristics, 91% of the EGFR mutations
appeared in patients over 60 years of age (p 0.02).
Patients with EGFR mutations, particularly exon 19
deletions (83%) responded to TKIs either as partial
response (50%) or stable disease (33%) (p 0.024). The
presence of EGFR exon 19 deletions were associated
with metastatic NSCLC, with bone and brain metastases
as the most common secondary localization of disease
(p 0.044).
